AU2003211093A8 - Inhibitors of rgs proteins - Google Patents

Inhibitors of rgs proteins

Info

Publication number
AU2003211093A8
AU2003211093A8 AU2003211093A AU2003211093A AU2003211093A8 AU 2003211093 A8 AU2003211093 A8 AU 2003211093A8 AU 2003211093 A AU2003211093 A AU 2003211093A AU 2003211093 A AU2003211093 A AU 2003211093A AU 2003211093 A8 AU2003211093 A8 AU 2003211093A8
Authority
AU
Australia
Prior art keywords
inhibitors
rgs proteins
rgs
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003211093A
Other versions
AU2003211093A1 (en
Inventor
Richard R Neubig
Huailing Zhong
Roger Sunahara
Yafei Jin
Henry I Mosberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of AU2003211093A8 publication Critical patent/AU2003211093A8/en
Publication of AU2003211093A1 publication Critical patent/AU2003211093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU2003211093A 2002-02-15 2003-02-13 Inhibitors of rgs proteins Abandoned AU2003211093A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35741802P 2002-02-15 2002-02-15
US60/357,418 2002-02-15
US10/365,840 2003-02-13
PCT/US2003/004616 WO2003070892A2 (en) 2002-02-15 2003-02-13 Inhibitors of rgs proteins
US10/365,840 US7432242B2 (en) 2002-02-15 2003-02-13 Inhibitors of RGS proteins

Publications (2)

Publication Number Publication Date
AU2003211093A8 true AU2003211093A8 (en) 2003-09-09
AU2003211093A1 AU2003211093A1 (en) 2003-09-09

Family

ID=27760462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003211093A Abandoned AU2003211093A1 (en) 2002-02-15 2003-02-13 Inhibitors of rgs proteins

Country Status (3)

Country Link
US (1) US7432242B2 (en)
AU (1) AU2003211093A1 (en)
WO (1) WO2003070892A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
WO2005003288A2 (en) * 2003-07-02 2005-01-13 Elena Jazin Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof
JP2009544330A (en) * 2006-07-26 2009-12-17 ザ・コカ−コーラ・カンパニー Methods for identifying modulators of RGS21 activity, compositions comprising RGS21 modulators, and methods of use thereof for modulating taste
WO2008076904A1 (en) 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
BRPI0809366B8 (en) 2007-03-28 2021-05-25 Harvard College substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2011038054A1 (en) * 2009-09-24 2011-03-31 The Board Of Trustees Of The University Of Illinois COMPOSITIONS AND METHODS FOR INHIBITING Gα PROTEIN SIGNALING
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102565414B (en) * 2010-12-13 2014-01-29 天津市新药安全评价研究中心 Method for determining combination of polypeptide drug and plasma protein
WO2013049026A2 (en) * 2011-09-29 2013-04-04 The Uab Research Foundation Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine
CN108929375A (en) 2011-10-18 2018-12-04 爱勒让治疗公司 Peptidomimetic macrocyclic compound
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9540620B2 (en) 2012-05-03 2017-01-10 The University Of North Carolina At Chapel Hill Methods and compositions for modulating G-alpha-Q signaling
JP6526563B2 (en) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド Disubstituted amino acids and methods for their preparation and use
US20170145058A1 (en) * 2014-05-09 2017-05-25 Bayer Pharma Aktiengesellschaft Method for targeted conjugation of peptides and proteins by paired c2 bridging of cysteine amino acids
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
MX2017011834A (en) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US5929207A (en) 1996-01-12 1999-07-27 Massachusetts Institute Of Technology Regulators of G-protein signalling
US6069296A (en) 1995-06-02 2000-05-30 Massachusetts Institute Of Technology Regulators of G-protein signalling
US6274362B1 (en) 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof

Also Published As

Publication number Publication date
US20040053821A1 (en) 2004-03-18
AU2003211093A1 (en) 2003-09-09
WO2003070892A2 (en) 2003-08-28
WO2003070892A3 (en) 2004-11-25
US7432242B2 (en) 2008-10-07

Similar Documents

Publication Publication Date Title
AU2003211093A8 (en) Inhibitors of rgs proteins
HK1077762A1 (en) INHIBITORS OF TFGβ
PL377825A1 (en) Diaminotriazoles useful as inhibitors of protein kinases
EG25482A (en) Inhibitors
HK1072545A1 (en) Novel inhibitors of kinases
HK1080069A1 (en) Nitrooxyderivatives of cyclooxygenase-2 inhibitors
EP1499336A4 (en) Protease inhibitors
AU2003217105A8 (en) Novel of cytokine inhibitors
EP1532133A4 (en) Nf-:b inhibitors
AU2003269984A8 (en) Protease inhibitors
AU2003282338A8 (en) Determination of protein function
AU2003258941A8 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
AU2003216848A1 (en) Deracemisation of amines
AU2003304374A8 (en) Peptide inhibitors of beta-lactamases
AU2003263738A8 (en) Protease inhibitors
AU2003262638A8 (en) Biotinylation of proteins
EP1545520A4 (en) Multifunctional cox-2 inhibitors
AU2003233642A8 (en) Protease inhibitors
AU2003304496A8 (en) Protease inhibitors
PL356853A1 (en) Application of bacteriphages
AU2003265240A8 (en) Protease inhibitors
AU2003269878A8 (en) Protease inhibitors
AU2003215235A8 (en) Cks1 inhibitors
AU2002952309A0 (en) Inhibitors of biotin protein legase
ZA200500492B (en) Novel inhibitors of kinases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase